Payment overview · 2025
General Payments
$722.09
30 reported records · 13 companies
Healthcare provider profile · identity verified
Daniel D Dugi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CUERO, TX · NPI 1598701344
Verified facts
What the public records show
CMS Open Payments records show Daniel D Dugi, M.D. received $722.09 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.78 | 16.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.98 | 13.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.64 | 12.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.35 | 9.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.77 | 9.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.36 | 8.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.33 | 7.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.39 | 7.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.04 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.34 | 3.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.14 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.86 | 2.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $722.09 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $97.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.64 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.77 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $61.44 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.34 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $57.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $54.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.61 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 219 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 301 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 202 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 97 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
219 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
301 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
97 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
434 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 870 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 776 | 130 |
| Furosemide | Furosemide | 727 | 126 |
| Gabapentin | Gabapentin | 636 | 105 |
| Potassium Chloride | Potassium Chloride | 636 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 132 |
| Sertraline Hcl | Sertraline Hcl | 562 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 543 | 137 |
| Donepezil Hcl | Donepezil Hcl | 518 | 55 |
| Trazodone Hcl | Trazodone Hcl | 472 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 85 |
| Losartan Potassium | Losartan Potassium | 443 | 94 |
| Eliquis | Apixaban | 434 | 56 |
| Metformin Hcl | Metformin Hcl | 386 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 373 | 72 |
| Famotidine | Famotidine | 360 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 346 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 343 | 67 |
| Lisinopril | Lisinopril | 322 | 72 |
| Divalproex Sodium | Divalproex Sodium | 316 | 35 |
| Mounjaro | Tirzepatide | 301 | 41 |
| Memantine Hcl | Memantine Hcl | 294 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 291 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 70 |
| Tramadol Hcl | Tramadol Hcl | 287 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 56 |
| Allopurinol | Allopurinol | 243 | 49 |
| Omeprazole | Omeprazole | 227 | 51 |
| Jardiance | Empagliflozin | 219 | 34 |
| Januvia | Sitagliptin Phosphate | 217 | 19 |
| Alprazolam | Alprazolam | 216 | 54 |
| Glipizide | Glipizide | 216 | 42 |
| Ozempic | Semaglutide | 202 | 40 |
| Carvedilol | Carvedilol | 191 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 190 | 20 |
| Prednisone | Prednisone | 174 | 118 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 44 |
| Myrbetriq | Mirabegron | 170 | 22 |
| Meloxicam | Meloxicam | 167 | 41 |
| Simvastatin | Simvastatin | 162 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 20 |
| Spironolactone | Spironolactone | 152 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 146 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 137 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 33 |
| Montelukast Sodium | Montelukast Sodium | 136 | 42 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 125 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 121 | 16 |
| Levetiracetam | Levetiracetam | 116 | 14 |
| Pregabalin | Pregabalin | 116 | 35 |
| Lorazepam | Lorazepam | 113 | 21 |
| Ezetimibe | Ezetimibe | 109 | 24 |
| Farxiga | Dapagliflozin Propanediol | 106 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 24 |
| Minocycline Hcl | Minocycline Hcl | 103 | 66 |
| Memantine Hcl Er | Memantine Hcl | 102 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 71 |
| Bumetanide | Bumetanide | 99 | 17 |
| Entresto | Sacubitril/Valsartan | 97 | 12 |
| Rexulti | Brexpiprazole | 97 | suppressed |
| Enulose | Lactulose | 96 | 19 |
| Lactulose | Lactulose | 95 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 15 |
| Clonazepam | Clonazepam | 92 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 92 | 22 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 88 | suppressed |
| Azithromycin | Azithromycin | 86 | 67 |
| Metoclopramide Hcl | Metoclopramide Hcl | 85 | 19 |
| Finasteride | Finasteride | 82 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 81 | suppressed |
| Mirtazapine | Mirtazapine | 78 | 11 |
| Naproxen | Naproxen | 76 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 76 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 75 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 15 |
| Digoxin | Digoxin | 71 | 12 |
| Mupirocin | Mupirocin | 71 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 27 |
| Amoxicillin | Amoxicillin | 67 | 52 |
| Baclofen | Baclofen | 66 | 13 |
| Cephalexin | Cephalexin | 66 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Atenolol | Atenolol | 65 | 13 |
| Glyxambi | Empagliflozin/Linagliptin | 64 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 63 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 62 | 17 |
| Lithium Carbonate Er | Lithium Carbonate | 62 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Novolog | Insulin Aspart | 59 | suppressed |
| Paliperidone Er | Paliperidone | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Levofloxacin | Levofloxacin | 55 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 12 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Olanzapine | Olanzapine | 54 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 11 |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Celecoxib | Celecoxib | 51 | 15 |
| Fluconazole | Fluconazole | 51 | 34 |
| Levemir | Insulin Detemir | 51 | suppressed |
| Gemfibrozil | Gemfibrozil | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 48 | 24 |
| Risperidone | Risperidone | 48 | suppressed |
| Telmisartan | Telmisartan | 47 | 11 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Novolin R | Insulin Regular, Human | 40 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 40 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 18 |
| Lamotrigine Odt | Lamotrigine | 39 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 35 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 18 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 14 |
| Metronidazole | Metronidazole | 29 | 21 |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 20 |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 13 |
| Estradiol | Estradiol | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | 13 |
| Constulose | Lactulose | 19 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Ofloxacin | Ofloxacin | 19 | 16 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clarithromycin | Clarithromycin | 16 | 16 |
| Haloperidol Lactate | Haloperidol Lactate | 16 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 14 | suppressed |
| Ivermectin | Ivermectin | 14 | 12 |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vyzulta | Latanoprostene Bunod | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $722.09 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, FARXIGA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, WATCHMAN FLX, XHANCE, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error